Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.
Researchers at the National Cancer Institute (NCI) developed a novel biophysical technique to purify extracellular vesicles (EVs) from contaminants such as proteins and unbound labels. The NCI seeks licensees and/or co-development research collaborations to further advance this technology for EV-based biomarkers and therapeutics to treat a wide range of diseases.
The National Institute of Child Health & Human Development (NICHD), Program in Genomics of Differentiation, seeks interested parties to further co-develop small molecule inhibitors of RNase H1, especially in regards to genome instability, transcription, and translation.
The National Cancer Institute (NCI) seeks licensees for a library of cell lines stably expressing common tumor-specific antigens and human leukocyte antigens (HLAs) that can be used to identify, isolate, and expand tumor-reactive T cells.
The National Cancer Institute (NCI) seeks licensees for a mouse model of CD4+ T cell deficiency. The mice carry alleles with germline and conditional deletions of the Zbtb7b gene encoding the zinc finger transcription factor ThPOK or cKrox, essential for the development and function of CD4+ T cells.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).